+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

06 June 2019
Pharma

Visiongain has launched a new pharma report Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy.

Over the past ten years, there has been a paradigm shift in the treatment of cancer, driven by advances in personalised medicine and immuno-oncology. The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.

The lead analyst of the report commented "The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously. Thus, Visiongain believes that the focus on oncology and precision oncology diagnostics will remain high over the next decade driven by the ongoing research and development and growing number of partnerships between pharmaceutical and diagnostics players in this field.

Novel trends such as development of liquid biopsy-based tests will revolutionise the future of precision cancer diagnostic tests and as a result of this; the market will continue to achieve strong revenue growth."

Leading companies featured in the report include Abbott Laboratories, Agilent Technologies, Inc., bioMerieux SA, Genomic Health, Inc., Illumina, Inc., Myriad Genetics, Inc., Qiagen N.V., Roche Holding AG, Siemens Healthineers, Thermo Fisher Scientific, Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Antibiotics Market Report 2023-2033

The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

31 January 2023

Read

Visiongain Publishes Human Microbiome Market Report 2023-2033

The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

30 January 2023

Read